Noevir Raysela Uv Shield Primer Cream
NDC Package 24509-0001-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Noevir Raysela Uv Shield Primer (zinc oxide, octinoxate) cream is for sunscreen use:apply liberally 15 minutes before sun exposure. This formulation utilizes a cream delivery system. Marketed by Nippon Shikizai, Inc., this product is identified by NDC 24509-0001 and is authorized under FDA application M020.

Identification & Billing

NDC Package Code
24509-0001-1
Package Description
1 TUBE in 1 BOX / 50 g in 1 TUBE
Product Code
24509-0001
11-Digit Billing Format
24509000101

Clinical Specifications

Proprietary Name
Noevir Raysela Uv Shield Primer
Non-Proprietary Name
Zinc Oxide, Octinoxate
Substance Name
Octinoxate; Zinc Oxide
Dosage Form
Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Cutaneous - Administration to the skin.
Active Ingredient(s)
Usage Information
For sunscreen use:apply liberally 15 minutes before sun exposure. reapply at least every 2 hours. use a water-resistant sunscreen if swimming or sweating. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:limit time in the sun, especially from 10 a.m. - 2 p.m wear long-sleeve-shirts pants, hats and sunglasses. children under 6 months: Ask a doctor.

Regulatory & Marketing

Labeler Name
Nippon Shikizai, Inc.
Product Type
Human Otc Drug
FDA Application #
M020
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
04-10-2018
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24509-0001-1 identifies a specific commercial package of 1 tube in 1 box / 50 g in 1 tube of Noevir Raysela Uv Shield Primer, a human over the counter drug labeled by Nippon Shikizai, Inc.. This cream is formulated for cutaneous use and contains octinoxate; zinc oxide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nippon Shikizai, Inc. on April 10, 2018. The current certification is valid through December 31, 2026.

How is this Nippon Shikizai, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24509000101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
24509-0001-1
11-Digit CMS (5-4-2)
24509-0001-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.